Psychopharmacology for Neurologists

Steven L Dubovsky; Amelia N Dubovsky

doi:10.1055/s-0029-1223877

Seminars in Neurology, Inhaltsverzeichnis

Semin Neurol 2009; 29(3): 200-219
DOI: 10.1055/s-0029-1223877

Psychopharmacology for Neurologists

Steven L. Dubovsky¹ ^, ² ^, ³ , Amelia N. Dubovsky⁴

¹Department of Psychiatry, University at Buffalo, Buffalo, New York
²Department of Psychiatry, University of Colorado, Denver, Colorado
³Department of Medicine, University of Colorado, Denver, Colorado
⁴Department of Psychiatry, Harvard University, Cambridge, Massachusetts

Abstract

ABSTRACT

Psychiatric disorders are common in neurological patients, and psychopharmacological agents are frequently used to treat agitation and other problems in neurological practice. Antidepressants are effective for depression caused by neurological illness, but they can interact with other medications. Antianxiety drugs can aggravate cognitive disorders and should be used cautiously in this context. Antipsychotic drugs can be useful for acute agitation, but they are being found to be neither effective nor safe for chronic nonpsychotic agitation. Other agents such as β blockers and serotonergic agents are being found to be more useful. Uses, doses, adverse effects, and interactions of psychiatric medications in neurology are summarized in this article, and suggestions are provided for the practical application of these treatments.

KEYWORDS

Psychopharmacology - medication - psychiatric - adverse effects - agitation - antidepressant - antipsychotic - anxiolytic

Volltext

Referenzen

REFERENCES

1 Schildkraut J J, Schanberg S M, Breese G R, Kopin I J. Norepinephrine metabolism and drugs used in the affective disorders: a possible mechanism of action. Am J Psychiatry. 1967; 124(5) 600-608
2 Gold P W, Licinio J, Wong M L, Chrousos G P. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and the mechanisms of action of antidepressant drugs. Ann N Y Acad Sci. 1995; 771 716-729
3 Shelton R C. Intracellular mechanisms of antidepressant drug action. Harv Rev Psychiatry. 2000; 8(4) 161-174
4 Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev. 2006; 58(1) 115-134
5 Caley C F. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother. 1997; 31(12) 1481-1489
6 Dubovsky S L. Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. J Clin Psychiatry. 1994; 55(Suppl) 34-44
7 Gerber P E, Lynd L D. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998; 32(6) 692-698
8 Gill H S, DeVane C L, Risch S C. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol. 1997; 17(5) 377-389
9 Dubovsky S L, Thomas M. Tardive dyskinesia associated with fluoxetine. Psychiatr Serv. 1996; 47(9) 991-993
10 Movig K L, Leufkens H G, Lenderink A W et al.. Association between antidepressant drug use and hyponatraemia: a case-control study. Br J Clin Pharmacol. 2002; 53(4) 363-369
11 Dubovsky S L. Clinical Guide to Psychotropic Medications. New York, NY; WW Norton 2005
12 Mukherjee S, Sackeim H A, Schnur D B. Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience. Am J Psychiatry. 1994; 151(2) 169-176
13 Devanand D P, Dwork A J, Hutchinson E R, Bolwig T G, Sackeim H A. Does ECT alter brain structure?. Am J Psychiatry. 1994; 151(7) 957-970
14 Gwinn R P, Kondratyev A, Gale K. Time-dependent increase in basic fibroblast growth factor protein in limbic regions following electroshock seizures. Neuroscience. 2002; 114(2) 403-409
15 Taylor S M. Electroconvulsive therapy, brain-derived neurotrophic factor, and possible neurorestorative benefit of the clinical application of electroconvulsive therapy. J ECT. 2008; 24(2) 160-165
16 Dubovsky S L. Using electroconvulsive therapy for patients with neurological disease. Hosp Community Psychiatry. 1986; 37(8) 819-825
17 Krueger R B, Fama J M, Devanand D P, Prudic J, Sackeim H A. Does ECT permanently alter seizure threshold?. Biol Psychiatry. 1993; 33(4) 272-276
18 Aarsland D, Larsen J P, Waage O, Langeveld J H. Maintenance electroconvulsive therapy for Parkinson's disease. Convuls Ther. 1997; 13(4) 274-277
19 Moellentine C, Rummans T A, Ahlskog J E et al.. Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neurosci. 1998; 10(2) 187-193
20 Kennedy R, Mittal D, O'Jile J. Electroconvulsive therapy in movement disorders: an update. J Neuropsychiatry Clin Neurosci. 2003; 15(4) 407-421
21 Andrade C, Kurinji S. Continuation and maintenance ECT: a review of recent research. J ECT. 2002; 18(3) 149-158
22 Weiner R D. American Psychiatric Association Committee on Electroconvulsive Therapy .The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. Washington, DC; American Psychiatric Association 1990
23 Dubovsky S L. Electroconvulsive therapy. In: Kaplan HI, Sadock BJ Comprehensive Textbook of Psychiatry/VI. 6th ed. Baltimore, MD; Williams and Wilkins 1995: 2129-2140
24 Dannon P N, Dolberg O T, Schreiber S, Grunhaus L. Three and six-month outcome following courses of either ECT or rTMS in a population of severely depressed individuals—preliminary report. Biol Psychiatry. 2002; 51(8) 687-690
25 Grunhaus L, Schreiber S, Dolberg O T, Polak D, Dannon P N. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. Biol Psychiatry. 2003; 53(4) 324-331
26 Kozel F A, George M S. Meta-analysis of left prefrontal repetitive transcranial magnetic stimulation (rTMS) to treat depression. J Psychiatr Pract. 2002; 8 270-275
27 Furukawa T A, Streiner D L, Young L T. Antidepressant and benzodiazepine for major depression. Cochrane Database Syst Rev. 2002; (1) CD001026
28 Dubovsky S L. Agents acting on the benzodiazepine receptor. In: Sadock B, Sadock V, Ruiz P Comprehensive Textbook of Psychiatry. 9th ed. Baltimore, MD; Williams and Wilkins 2009
29 Busto U, Sellers E M, Naranjo C A, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med. 1986; 315(14) 854-859
30 Brooks J O, Hoblyn J C. Neurocognitive costs and benefits of psychotropic medications in older adults. J Geriatr Psychiatry Neurol. 2007; 20(4) 199-214
31 Smith D E, Wesson D R. Benzodiazepines and other sedative-hypnotics. In: Galanter M, Kleber HD American Psychiatric Press Textbook of Substance Abuse Treatment, 2nd ed. Washington, DC; American Psychiatric Press 1999: 239-250
32 Smith D E, Wesson D R. Phenobarbital technique for treatment of barbiturate dependence. Arch Gen Psychiatry. 1971; 24(1) 56-60
33 Garfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch Intern Med. 1999; 159(20) 2456-2460
34 Pande A C, Pollack M H, Crockatt J G et al.. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000; 20(4) 467-471
35 Pande A C, Feltner D E, Jefferson J W et al.. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004; 24(2) 141-149
36 Dubovsky S L. Agents acting on the benzodiazepine receptor. In: Sadock B, Sadock V, Ruiz P Comprehensive Textbook of Psychiatry. 10th ed. Baltimore, MD; Williams and Wilkins 2009
37 Davis J M, Chen N, Glick I D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003; 60(6) 553-564
38 Lieberman J A, Stroup T S, McEvoy J P Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12) 1209-1223
39 Jones P B, Barnes T R, Davies L et al.. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006; 63(10) 1079-1087
40 Marder S R, Essock S M, Miller A L et al.. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull. 2002; 28(1) 5-16
41 Tohen M, Calabrese J R, Sachs G S et al.. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006; 163(2) 247-256
42 Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008; 109(3) 251-263
43 Allison D B, Mentore J L, Heo M et al.. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156(11) 1686-1696
44 Gianfrancesco F D, Grogg A L, Mahmoud R A, Wang R H, Nasrallah H A. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry. 2002; 63(10) 920-930
45 American Diabetes Association . Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004; 27(2) 596-601
46 Reilly J G, Ayis S A, Ferrier I N, Jones S J, Thomas S HL. Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry. 2002; 180 515-522
47 Ray W A, Chung C P, Murray K T, Hall K, Stein C M. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009; 360(3) 225-235
48 Shale J H, Shale C M, Mastin W D. A review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. J Clin Psychiatry. 2003; 64(5) 500-505
49 Passmore M J, Gardner D M, Polak Y, Rabheru K. Alternatives to atypical antipsychotics for the management of dementia-related agitation. Drugs Aging. 2008; 25(5) 381-398
50 Friedman J H. Atypical antipsychotics in the elderly with Parkinson disease and the “black box” warning. Neurology. 2006; 67(4) 564-566
51 Rabins P V, Lyketsos C G. Antipsychotic drugs in dementia: what should be made of the risks?. JAMA. 2005; 294(15) 1963-1965
52 Finkel S, Kozma C, Long S et al.. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr. 2005; 17(4) 617-629
53 Kales H C, Valenstein M, Kim H M et al.. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry. 2007; 164(10) 1568-1576, quiz 1623
54 Brodtkorb E, Mula M. Optimizing therapy of seizures in adult patients with psychiatric comorbidity. Neurology. 2006; 67(12, Suppl 4) S39-S44
55 Kurlan R, Cummings J, Raman R, Thal L. Alzheimer's Disease Cooperative Study Group . Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007; 68(17) 1356-1363
56 Chacko R C, Hurley R A, Harper R G, Jankovic J, Cardoso F. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1995; 7(4) 471-475
57 Strawn J R, Keck Jr P EJ, Caroff S N. Neuroleptic malignant syndrome. Am J Psychiatry. 2007; 164(6) 870-876
58 Panitch H S, Thisted R A, Smith R A Psuedobulbar Affect in Multiple Sclerosis Study Group et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006; 59(5) 780-787
59 Loj J, Solomon G D. Migraine prophylaxis: who, why, and how. Cleve Clin J Med. 2006; 73(9) 793-794, 797, 800–801 passim
60 Saarto T, Wiffen P J. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007; (4) CD005454
61 Battaglia J, Lindborg S R, Alaka K, Meehan K, Wright P. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med. 2003; 21(3) 192-198
62 Battaglia J, Moss S, Rush J et al.. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med. 1997; 15(4) 335-340
63 Lukens T W, Wolf S J, Edlow J A American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the Emergency Department et al. Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. Ann Emerg Med. 2006; 47(1) 79-99
64 Zuidema S U, van Lersel M B, Koopmans R T, Verhey F R, Olde Rikkert M G. Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review. Ned Tijdschr Geneeskd. 2006; 150 1565-1573
65 Miyaji S, Yamamoto K, Hoshino S, Yamamoto H, Sakai Y, Miyaoka H. Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients. Psychiatry Clin Neurosci. 2007; 61(3) 275-282
66 Riker R R, Fraser G L, Cox P M. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med. 1994; 22(3) 433-440
67 Fernandez F, Holmes V F, Adams F, Kavanaugh J J. Treatment of severe, refractory agitation with a haloperidol drip. J Clin Psychiatry. 1988; 49(6) 239-241
68 Hassaballa H A, Balk R A. Torsade de pointes associated with the administration of intravenous haloperidol: a review of the literature and practical guidelines for use. Expert Opin Drug Saf. 2003; 2(6) 543-547
69 Tisdale J E, Rasty S, Padhi I D, Sharma N D, Rosman H. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of torsades de pointes. J Clin Pharmacol. 2001; 41(12) 1310-1318
70 Schneider L S, Dagerman K S, Insel P S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006; 14(3) 191-210
71 Schneider L S, Tariot P N, Dagerman K S CATIE-AD Study Group et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006; 355(15) 1525-1538
72 Sultzer D L, Davis S M, Tariot P N CATIE-AD Study Group et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008; 165(7) 844-854
73 Selbaek G, Kirkevold Ø, Engedal K. The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes—a 12-month follow-up study. Am J Geriatr Psychiatry. 2008; 16(7) 528-536
74 Lavretsky H. Neuropsychiatric symptoms in Alzheimer disease and related disorders: why do treatments work in clinical practice but not in the randomized trials?. Am J Geriatr Psychiatry. 2008; 16(7) 523-527
75 Pollock B G, Mulsant B H, Rosen J et al.. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry. 2007; 15(11) 942-952
76 Dubovsky S L, Thomas M. Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction. J Psychosom Res. 1995; 39(4) 429-444
77 Cantillon M, Brunswick R, Molina D, Bahro M. Buspirone vs haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer's disease. Am J Geriatr Psychiatry. 1996; 4 263-267
78 Brooke M M, Patterson D R, Questad K A, Cardenas D, Farrel-Roberts L. The treatment of agitation during initial hospitalization after traumatic brain injury. Arch Phys Med Rehabil. 1992; 73(10) 917-921
79 Weiler P G, Mungas D, Bernick C. Propranolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatry Neurol. 1988; 1(4) 226-230
80 Bearden C E, Thompson P M, Dalwani M et al.. Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry. 2007; 62(1) 7-16
81 Ramasubbu R, Kennedy S H. Factors complicating the diagnosis of depression in cerebrovascular disease, Part II—neurological deficits and various assessment methods. Can J Psychiatry. 1994; 39(10) 601-607
82 Ross E D. The aprosodias. Functional-anatomic organization of the affective components of language in the right hemisphere. Arch Neurol. 1981; 38(9) 561-569
83 Van Someren E JW, Kessler A, Mirmiran M, Swaab D F. Indirect bright light improves circadian rest-activity rhythm disturbances in demented patients. Biol Psychiatry. 1997; 41(9) 955-963
84 Cornélissen G, Halberg F, Burioka N, Perfetto F, Tarquini R, Bakken E E. Do plasma melatonin concentrations decline with age?. Am J Med. 2000; 109(4) 343-345
85 Okuma T, Kishimoto A. A history of investigation on the mood stabilizing effect of carbamazepine in Japan. Psychiatry Clin Neurosci. 1998; 52(1) 3-12
86 Freeman T W, Clothier J L, Pazzaglia P, Lesem M D, Swann A C. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry. 1992; 149(1) 108-111
87 Allen M H, Hirschfeld R M, Wozniak P J, Baker J D, Bowden C L. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry. 2006; 163 272-275
88 Conway C R, Chibnall J T, Nelson L A et al.. An open-label trial of adjunctive oxcarbazepine for bipolar disorder. J Clin Psychopharmacol. 2006; 26(1) 95-97
89 Ettinger A B. Psychotropic effects of antiepileptic drugs. Neurology. 2006; 67(11) 1916-1925
90 Calabrese J R, Bowden C L, Sachs G Lamictal 605 Study Group et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003; 64(9) 1013-1024
91 Bowden C L, Calabrese J R, Sachs G Lamictal 606 Study Group et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003; 60(4) 392-400
92 Reimers A, Skogvoll E, Sund J K, Spigset O. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol. 2005; 25(4) 342-348
93 Pande A C, Davidson J R, Jefferson J W et al.. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999; 19(4) 341-348
94 Pohl R B, Feltner D E, Fieve R R, Pande A C. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005; 25(2) 151-158
95 Feltner D E, Crockatt J G, Dubovsky S J et al.. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003; 23(3) 240-249
96 Roy Chengappa K N, Schwarzman L K, Hulihan J F, Xiang J, Rosenthal N R. Clinical Affairs Product Support Study-168 Investigators . Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J Clin Psychiatry. 2006; 67(11) 1698-1706
97 Kushner S F, Khan A, Lane R, Olson W H. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord. 2006; 8(1) 15-27
98 Vasudev K, Macritchie K, Geddes J R, Watson S, Young A H. Topiramate for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev. 2006; (1) CD003384
99 Krüger S, Sarkar R, Pietsch R, Hasenclever D, Bräunig P. Levetiracetam as monotherapy or add-on to valproate in the treatment of acute mania-a randomized open-label study. Psychopharmacology (Berl). 2008; 198(2) 297-299
100 Post R M, Altshuler L L, Frye M A et al.. Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. J Clin Psychiatry. 2005; 66(3) 370-374
101 Young A H, Geddes J R, Macritchie K, Rao S N, Vasudev A. Tiagabine in the maintenance treatment of bipolar disorders. Cochrane Database Syst Rev. 2006; (3) CD005173
102 Ghaemi S N, Shirzadi A A, Klugman J, Berv D A, Pardo T B, Filkowski M M. Is adjunctive open-label zonisamide effective for bipolar disorder?. J Affect Disord. 2008; 105(1-3) 311-314
103 Wang P W, Yang Y S, Chandler R A et al.. Adjunctive zonisamide for weight loss in euthymic bipolar disorder patients: a pilot study. J Psychiatr Res. 2008; 42(6) 451-457
104 Corrigan M H, Denahan A Q, Wright C E, Ragual R J, Evans D L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000; 11(2) 58-65
105 Lattanzi L, Dell'Osso L, Cassano P et al.. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord. 2002; 4(5) 307-314
106 Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H S. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry. 2001; 34(4) 137-141
107 Rush A J, Sackeim H A, Marangell L B et al.. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry. 2005; 58(5) 355-363
108 Rush A J, George M S, Sackeim H A et al.. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry. 2000; 47(4) 276-286
109 Rush A J, Marangell L B, Sackeim H A et al.. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005; 58(5) 347-354
110 Sackeim H A, Brannan S K, Rush A J, George M S, Marangell L B, Allen J. Durability of antidepressant response to vagus nerve stimulation (VNS). Int J Neuropsychopharmacol. 2007; 10(6) 817-826
111 Lozano A M, Mayberg H S, Giacobbe P, Hamani C, Craddock R C, Kennedy S H. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry. 2008; 64(6) 461-467
112 Mallet L, Polosan M, Jaafari N et al.. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med. 2008; 359 2121-2134

Steven L DubovskyM.D.

462 Grider Street

Buffalo, NY 14215

eMail: dubovsky@buffalo.edu